Gilead Sciences (GILD) Stock Statistics & Valuation Metrics
Total Valuation
Gilead Sciences has a market cap or net worth of MXN 3.98T. The enterprise value is MXN 204.66B.
- Market Cap
- MXN 3.98T
- Enterprise Value
- MXN 204.66B
Share Statistics
Gilead Sciences has 1,239,955,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,239,955,200
- Owned by Insiders
- 0.08%
- Owned by Institutions
- 60.35%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 20.32%.
- Return on Equity (ROE)
- 0.37
- Return on Assets (ROA)
- 0.14
- Return on Invested Capital (ROIC)
- 20.32%
- Return on Capital Employed (ROCE)
- 0.25
- Revenue Per Employee
- 1.73M
- Profits Per Employee
- 500.59K
- Employee Count
- 17,000
- Asset Turnover
- 0.50
- Inventory Turnover
- 3.51
Valuation Ratios
The current PE Ratio of Gilead Sciences is -55.06. Gilead Sciences’s PEG ratio is 0.42.
- PE Ratio
- -55.06
- PS Ratio
- 6.83
- PB Ratio
- 16.26
- Price to FCF
- 15.08
- Price to Operating Cash Flow
- 14.64
- PEG Ratio
- 0.42
Income Statement
In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.
- Revenue
- 29.44B
- Gross Profit
- 23.21B
- Operating Income
- 11.70B
- Pretax Income
- 9.80B
- Net Income
- 8.51B
- EBITDA
- 13.58B
- Earnings Per Share (EPS)
- 6.84
Cash Flow
In the last 12 months, operating cash flow was 14.48B and capital expenditures -442.00M, giving a free cash flow of 14.04B billion.
- Operating Cash Flow
- 14.48B
- Free Cash Flow
- 14.04B
- Free Cash Flow per Share
- 11.30
Dividends & Yields
Gilead Sciences pays an annual dividend of ―, resulting in a dividend yield of 1.68%
- Dividend Per Share
- ―
- Dividend Yield
- 1.68%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.63%
- Earnings Yield
- -1.82%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- 46.20%
- 50-Day Moving Average
- 2650.82
- 200-Day Moving Average
- 2418.22
- Relative Strength Index (RSI)
- 87.94
- Average Volume (3m)
- 2,245
Important Dates
Gilead Sciences upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Gilead Sciences as a current ratio of 1.55, with Debt / Equity ratio of 109.84%
- Current Ratio
- 1.55
- Quick Ratio
- 1.40
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 1.28
- Interest Coverage Ratio
- 11.43
Taxes
In the past 12 months, Gilead Sciences has paid 1.29B in taxes.
- Income Tax
- 1.29B
- Effective Tax Rate
- 0.13
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 281.20, with an EV/FCF ratio of 16.49.
- EV to Sales
- 7.47
- EV to EBITDA
- 281.20
- EV to Free Cash Flow
- 16.49
- EV to Operating Cash Flow
- 15.98
Balance Sheet
Gilead Sciences has MXN 6.44B in cash and marketable securities with MXN 26.23B in debt, giving a net cash position of -MXN 19.79B billion.
- Cash & Marketable Securities
- MXN 6.44B
- Total Debt
- MXN 26.23B
- Net Cash
- -MXN 19.79B
- Net Cash Per Share
- -MXN 15.96
- Tangible Book Value Per Share
- -MXN 7.07
Margins
Gross margin is 79.93%, with operating margin of -4.38%, and net profit margin of -12.47%.
- Gross Margin
- 79.93%
- Operating Margin
- -4.38%
- Pretax Margin
- -8.17%
- Net Profit Margin
- -12.47%
- EBITDA Margin
- 2.66%
- EBIT Margin
- -6.43%
Analyst Forecast
The average price target for Gilead Sciences is MXN 3,244.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- MXN 3,244.14
- Price Target Upside
- 0.28% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 22
- Revenue Growth Forecast
- -4.01%
- EPS Growth Forecast
- -141.32%
Scores
- Smart Score
- 9
- AI Score
- ―